Mesa Laboratories Inc: Form 10-Q for the period ended Dec 31, 2018
Filed with the SEC on Feb 4, 2019 and accepted by EDGAR at Feb 4, 2019, 08:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2018-10-01 to 2018-12-31 | $11.0m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2018-04-01 to 2018-12-31 | $31.4m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2018-10-01 to 2018-12-31 | $15.6m | us-gaap:GrossProfit |
| Gross profit | 9 months2018-04-01 to 2018-12-31 | $45.3m | us-gaap:GrossProfit |
| Research and development | 3 months2018-10-01 to 2018-12-31 | $860.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2018-04-01 to 2018-12-31 | $2.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-10-01 to 2018-12-31 | $1.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2018-04-01 to 2018-12-31 | $7.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2018-10-01 to 2018-12-31 | $90.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2018-04-01 to 2018-12-31 | $572.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-10-01 to 2018-12-31 | $858.0k | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 9 months2018-04-01 to 2018-12-31 | $6.1m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2018-10-01 to 2018-12-31 | $0.21 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2018-04-01 to 2018-12-31 | $1.51 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2018-10-01 to 2018-12-31 | $0.22 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2018-04-01 to 2018-12-31 | $1.58 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2018-10-01 to 2018-12-31 | 4,045,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2018-04-01 to 2018-12-31 | 4,037,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2018-04-01 to 2018-12-31 | $20.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 9 months2018-04-01 to 2018-12-31 | $1.8m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2018-12-31 | $5.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-12-31 | $32.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-12-31 | $158.2m | us-gaap:Assets |
| Current liabilities | At period end2018-12-31 | $20.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-12-31 | $50.6m | us-gaap:Liabilities |
| Long-term debt | At period end2018-12-31 | $27.2m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2018-12-31 | $2.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2018-12-31 | $107.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-19-001738. Last ingested by Listed: Nov 13, 2026, 07:45 ET. Listed shows no prices and gives no investment advice.